Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Linde
LIN
|
$588M |
| 2 |
Apple
AAPL
|
$574M |
| 3 |
Illumina
ILMN
|
$398M |
| 4 |
Monster Beverage
MNST
|
$396M |
| 5 |
argenx
ARGX
|
$306M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$600M |
| 2 |
AbbVie
ABBV
|
$323M |
| 3 |
Sherwin-Williams
SHW
|
$309M |
| 4 |
Atlassian
TEAM
|
$250M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$241M |
Sector Composition
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.43% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Nuvation Bio
NUVB
$1.02B
| $84.7K | ﹤0.01% |
51,497
+27,122
| +111% | +$44.6K |
|
2627
Inovio Pharmaceuticals
INO
$132M
| $83.7K | ﹤0.01% |
102,114
+59,993
| +142% | +$49.2K |
|
|
CNSL
2628
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $82.6K | ﹤0.01% |
31,962
+17,462
| +120% | +$45.1K |
|
2629
Future Fuel
FF
$169M
| $82.3K | ﹤0.01% |
+11,173
| New | +$82.3K |
|
|
LOGC
2630
DELISTED
ContextLogic
LOGC
| $78.1K | ﹤0.01% |
178,522
+111,515
| +166% | +$48.8K |
|
|
AGEN
2631
Agenus
AGEN
$134M
| $77.5K | ﹤0.01% |
50,841
+17,397
| +52% | +$26.5K |
|
2632
Rimini Street
RMNI
$386M
| $77.1K | ﹤0.01% |
+18,743
| New | +$77.1K |
|
|
CTEV
2633
Claritev Corporation
CTEV
$1.13B
| $76.7K | ﹤0.01% |
73,054
+44,443
| +155% | +$46.7K |
|
2634
Aurora
AUR
$10.5B
| $76.1K | ﹤0.01% |
+54,775
| New | +$76.1K |
|
2635
Microvast
MVST
$842M
| $74.6K | ﹤0.01% |
59,925
+30,985
| +107% | +$38.6K |
|
|
KLRS
2636
Kalaris Therapeutics, Inc. Common Stock
KLRS
$72.8M
| $74.3K | ﹤0.01% |
+18,873
| New | +$74.3K |
|
2637
Kezar Life Sciences
KZR
$28.4M
| $73.6K | ﹤0.01% |
23,560
+12,323
| +110% | +$38.5K |
|
2638
Lexicon Pharmaceuticals
LXRX
$403M
| $69.4K | ﹤0.01% |
28,630
+17,269
| +152% | +$41.9K |
|
2639
Purple Innovation
PRPL
$118M
| $67.6K | ﹤0.01% |
25,756
+14,014
| +119% | +$36.8K |
|
2640
Heron Therapeutics
HRTX
$204M
| $67.5K | ﹤0.01% |
44,526
+26,787
| +151% | +$40.6K |
|
2641
Angi Inc
ANGI
$770M
| $67.3K | ﹤0.01% |
29,711
+16,633
| +127% | +$37.7K |
|
2642
Bridger Aerospace
BAER
$115M
| $67.2K | ﹤0.01% |
+14,772
| New | +$67.2K |
|
2643
Amneal Pharmaceuticals
AMRX
$2.97B
| $62.6K | ﹤0.01% |
44,720
+24,979
| +127% | +$35K |
|
|
BHIL
2644
DELISTED
Benson Hill, Inc.
BHIL
| $62.6K | ﹤0.01% |
55,136
+27,997
| +103% | +$31.8K |
|
|
WE
2645
DELISTED
WeWork Inc.
WE
| $62.2K | ﹤0.01% |
80,716
+41,433
| +105% | +$31.9K |
|
2646
Adicet Bio
ACET
$60.4M
| $61.2K | ﹤0.01% |
+10,632
| New | +$61.2K |
|
2647
Energy Vault
NRGV
$330M
| $60.1K | ﹤0.01% |
28,128
+16,523
| +142% | +$35.3K |
|
|
CMAX
2648
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $59.2K | ﹤0.01% |
22,219
+10,810
| +95% | +$28.8K |
|
2649
Seer Inc
SEER
$114M
| $58.9K | ﹤0.01% |
+15,299
| New | +$58.9K |
|
2650
Nektar Therapeutics
NKTR
$555M
| $57.8K | ﹤0.01% |
82,603
+46,128
| +126% | +$32.3K |
|